Inside the research

Eli Lilly and Company

LLY Research profile · latest available data

Price overview

$1,183.46

▲ +1.57 (+0.1%)

52w hi$1,280.34
52w lo$710.11
Vol1.92M
As of25 Sep 2026

The Verdict

Hold

Our score +0.07

Short-0.15
Medium+0.17
Long+0.31

computed 2026-09-27

Key fundamentals

Eli Lilly and Company

Healthcare · Drug Manufacturers - General

Market cap$1.06T
Enterprise value$1.10T
Trailing P/E39.69x
Forward P/E25.00x
EV / EBITDA26.39x
P / S (ttm)13.24x
Profit margin33.5%
Return on equity102.3%
Revenue growth+47.7%
Earnings growth+26.2%
Debt / equity162.07

Layer Breakdown

LayerRawContribution
Fundamental+0.27
Sector+0.08
Technical-0.08
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

United States · www.lilly.com

Risk Metrics

Beta vs SPX0.58
Corr SPX0.25
Annual vol37.9%
Annual ret+19.7%
Sharpe0.52
Max DD-32.9%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$1,209.14
High / Low$1,500.00 / $850.00
Median$1,250.00
Analysts29
Strong Buy6
Buy18
Hold6
Sell1
Strong Sell0

Recent rating actions

2026-05-05Guggenheim→ Buy
2026-05-05Barclays→ Overweight
2026-05-04Wolfe Research→ Outperform
2026-05-01Cantor Fitzgerald→ Overweight
2026-04-22Guggenheim→ Buy
2026-04-10Morgan Stanley→ Overweight

Officers & Board

DirectorMary Lynne Hedley since 2022
DirectorKimberly H. Johnson since 2021
DirectorGabrielle Sulzberger since 2021
DirectorKaren Walker since 2018
CEODavid A. Ricks since 2017
DirectorDavid A. Ricks since 2017
DirectorJamere Jackson since 2016
DirectorJuan R. Luciano since 2016
DirectorMarschall Stevens Runge since 2013
DirectorWilliam G. Kaelin since 2012
DirectorKatherine Baicker since 2011
DirectorRalph Alvarez since 2009
DirectorErik Fyrwald since 2005
FounderEli Lilly current
CEOJohn C. Lechleiter 2008–2016

Material Events

DateEvent8-K
2026-08-05Earnings Release, Exhibitsread
2026-05-20Other Material Event, Exhibitsread
2026-05-07Shareholder Voteread
2026-04-30Earnings Release, Exhibitsread
2026-02-04Earnings Release, Exhibitsread
2025-11-21Officer / Director Changeread
2025-10-30Earnings Release, Exhibitsread
2025-08-20Other Material Event, Exhibitsread
2025-08-07Earnings Release, Exhibitsread
2025-05-08Shareholder Voteread
2025-05-01Earnings Release, Exhibitsread
2025-02-12Other Material Event, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-10Zakrowski Donald ASVP, Finance, & CAOSell2.00K$2.37M
2026-08-07Hakim AnatEVP, GC & SecretarySell5.00K$5.95M
2026-08-01Seymour MelissaEVP, Global QualityOption exercise981—
2026-08-01Seymour MelissaEVP, Global QualityWithheld for tax439$504.00K
2026-07-20Fyrwald J ErikGrant9$9.92K
2026-07-20LUCIANO JUAN RGrant14$15.92K
2026-07-20Sulzberger GabrielleGrant4$4.96K
2026-07-20Alvarez RalphGrant11$12.42K
2026-06-15Sulzberger GabrielleGrant4$4.96K
2026-06-15LUCIANO JUAN RGrant14$15.92K

Flow & Concentration

Insider 180d net-$24.07M
Insider buys / sells0 / 4
Insider biasSellers
13F holders0
Top-5 share0.0%
HHI0 (—)

Dividends

Yield (TTM)0.27%
$ / share (TTM)$3.23
5y CAGR+15.2%

Annual dividend per share

2021$3.40
2022$3.92
2023$4.52
2024$5.20
2025$6.00
2026$1.73

Federal Contracts

AmountAgencyDescription
$229.74KDepartment of Veterans AffairsAMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN

SEC Filings

DateFormDoc
2026-08-114view
2026-08-104view
2026-08-0510-Qview
2026-08-058-Kview
2026-08-034view
2026-07-233view
2026-07-214view
2026-07-214view
2026-07-214view
2026-07-214view
2026-06-2311-Kview
2026-06-164view
2026-06-164view
2026-06-164view
2026-06-164view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$45.04B+5.1%
Net income$20.64B+14.9%
Cash from ops$16.81B+8.8%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$1,185.32$1,190.00$1,160.84$1,183.461.92M
Sep 24$1,156.67$1,197.79$1,151.00$1,181.892.42M
Sep 23$1,174.71$1,188.88$1,145.98$1,150.992.15M
Sep 22$1,146.15$1,180.53$1,139.26$1,170.142.45M
Sep 21$1,144.50$1,170.90$1,134.41$1,164.892.48M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →